RT Journal Article
SR Electronic
T1 Addressing unmet needs in the treatment of COPD
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 333
OP 344
DO 10.1183/09059180.00004014
VO 23
IS 133
A1 Francesco Patalano
A1 Donald Banerji
A1 Peter D’Andrea
A1 Robert Fogel
A1 Pablo Altman
A1 Paul Colthorpe
YR 2014
UL http://err.ersjournals.com/content/23/133/333.abstract
AB The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.